Join our journey as we discover novel and effective treatments for hard to cure cancers.
Demonstrated in vitro and in vivo efficacy against triple-negative breast cancer and prostate cancer.
Supported by Godavari Biorefineries Limited and strategic partnership with CROs for early and global clinical development expertise.
Over 40 preclinical compounds targeting a diverse range of cancers. One compound in Phase 1
Opportunity to contribute to significant advancements in cancer treatment with potential for financial returns.